Antiviral properties of potato glycoalkaloids
-
1
Aristotle University of Thessaloniki, Department of Pharmacology, Greece
Potato is part of everyday human food and its toxicity makes it a potential source of poisoning. Potato glycoalkaloids, and especially solanine and chaconine are extremely toxic for humans and animals. Nevertheless, the pharmacological properties of potato alkaloids make them useful tools in antiviral therapeutics.
Chaconine is the most effective compound of the potato GAs at inactivating herpes simplex virus (HSV) Solamargine and crude extract from Solanum americanum present antiviral properties against herpes viruses (HSV), herpes genitalis and herpes zoster).
According to studies in humans, it has been observed that local application of an hydrophilic cream containing either solamargine a crude extract from Solanum americanum fruit for three to ten days had a curing effect on HSV, herpes genitalis and herpes zoster viral infections. The carbohydrate moiety of Gas plays an important role in the interaction with membrane sugar receptors.
Further research on the antiviral properties of potato alkaloids may give new cheap and safe antiviral drugs for herpes viral infections in the future.
References
Paraskevi Papaioannidou, Ioannis Papaioannidis, Vassiliki Mirtsou-Fidani: Pharmacological properties of potato glycoalkaloids. Hellenic Medical and Pharmaceutical Review 2005, 2(2):3-7
Keywords:
potato glycoalkaloids,
chaconine,
Solanine,
solamargine,
Herpes virus
Conference:
8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010, Thessaloniki, Greece, 1 Oct - 5 Oct, 2010.
Presentation Type:
Poster
Topic:
Xenobiotic toxicity
Citation:
Papaioannidis
I and
Kyriakidis
I
(2010). Antiviral properties of potato glycoalkaloids.
Front. Pharmacol.
Conference Abstract:
8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010.
doi: 10.3389/conf.fphar.2010.60.00177
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
28 Oct 2010;
Published Online:
04 Nov 2010.
*
Correspondence:
Dr. Ioannis Kyriakidis, Aristotle University of Thessaloniki, Department of Pharmacology, Thessaloniki, Greece, kyriakidis@med.uoc.gr